Effect of Penetration Enhancers on Gel Formulation of Zidovudine: In Vivo and Ex Vivo Studies

References

1. ↵
   1. Wilson J. D.,
   2. Braunwald E.,
   3. Isselbacher K. J.,
   4. Peterdorf R. G.,
   5. Martin J. B.,
   6. Fauci A. S.,
   7. Root R. K.

   Harrison's Principles of Internal Medicine, 12th Ed.; McGraw-Hill: New York, 1991; pp 1402–1410.
2. ↵
   1. Naidoo P.

   Barriers to HIV care and treatment by doctors: a review of the literature. SA Fam. Pract. 2006, 48, 52.

   OpenUrl
3. ↵
   UNAIDS, AIDS epidemic update, 2007. Available online: http://www.unaids.org.
4. ↵
   1. Chinen J.,
   2. Shearer W. T.

   Secondary immunodeficiencies, including HIV infection. J. Allergy Clin. Immunol. 2008, 121 (2 Suppl.), 388–392.

   OpenUrl
5. ↵
   1. Lucas S.

   Update on the pathology of AIDS. Intensive Crit. Care Nurs. 2001, 17 (3), 155–166.

   OpenUrlPubMed
6. ↵
   1. Littman D. R.

   Chemokine receptors: keys to AIDS pathogenesis. Cell. 1988, 93 (5), 677–680.

   OpenUrl
7. ↵
   1. McArthur J. C.,
   2. Brew B. J.,
   3. Nath A.

   Neurological complications of HIV infection. Lancet Neurol. 2005, 4 (9), 543–555.

   OpenUrlCrossRefPubMedWeb of Science
8. ↵
   1. Jain S.,
   2. Umamaheshwari R. B.,
   3. Bhadra D.,
   4. Jain N. K.

   Ethosomes: a novel vesicular carrier for enhanced transdermal delivery of an anti-HIV agent. Indian J. Pharm. Sci. 2004, 66 (1), 72–81.

   OpenUrl
9. ↵
   1. Jain S.,
   2. Tiwari A. K.,
   3. Jain N. K.

   Sustained and targeted delivery of an anti-HIV agent using elastic liposomal formulation: mechanism of action. Curr. Drug Deliv. 2006, 3 (2), 157–166.

   OpenUrlPubMed
10. ↵
    1. Kieburtz K. D.,
    2. Seidlin M.,
    3. Lambert J. S.,
    4. Dolin R.,
    5. Reichman R.,
    6. Valentine F.

    Extended follow up of neuropathy in patients with AIDS and AIDS-related complex treated with dideoxyinosine. J. Acquir. Immune Defic. Syndr. 1992, 5 (1), 60–64.

    OpenUrlPubMedWeb of Science
11. ↵
    1. Klecker R. W.,
    2. Collins J. M.,
    3. Yarchoan R.,
    4. Thomas R.,
    5. Jenkins J. F.,
    6. Broder S.,
    7. Myers C. E.

    Plasma and cerebrospinal fluid pharmacokinetics of 3-azido-3-deoxythymidine: a novel pyrimidine analog with potential application for the treatment of patients with AIDS and related disease. Clin. Pharmacol. Ther. 1987, 41 (4), 407–412.

    OpenUrlPubMedWeb of Science
12. ↵
    1. Kuksal A.,
    2. Tiwary A. K.,
    3. Jain N. K.,
    4. Jain S.

    Formulation and In vitro, in vivo evaluation of extended-release matrix tablet of zidovudine: influence of combination of hydrophilic and hydrophobic matrix formers. AAPS PharmSciTech 2006, 7 (1), E1–E9.

    OpenUrl
13. ↵
    1. Kim D. D.,
    2. Chien Y. W.

    Simultaneous skin permeation of dideoxynucleoside-type anti-HIV drugs. J. Controlled Release 1996, 40 (1–2), 67–76.

    OpenUrl
14. ↵
    1. Kim D. D.,
    2. Chien Y. W.

    Transdermal delivery of dideoxynucleoside type anti-HIV drugs. Stability studies for hairless rat skin permeation. J. Pharm. Sci. 1995, 84 (9), 1061–1066.

    OpenUrlPubMed
15. ↵
    1. Narishetty S. T. K.,
    2. Panchagnula R.

    Transdermal delivery of zidovudine: effect of terpenes and their mechanism of action. J. Controlled Release 2004, 95 (3), 367–379.

    OpenUrlPubMed
16. ↵
    1. Thomas N. S.,
    2. Panchagnula R.

    Transdermal delivery of zidovudine: effect of vehicles on permeation across rat skin and their mechanism of action. Eur. J. Pharm. Sci. 2003, 18 (1), 71–79.

    OpenUrlPubMed
17. ↵
    1. Kararli T. T.,
    2. Kirchhoff C. F.,
    3. Penzotti S. C.

    Enhancement of transdermal transport of azidothymidine with novel terpene and terpene-like enhancers: in vivo–in vitro correlations. J. Controlled Release 1995, 34 (1), 43–51.

    OpenUrlCrossRef
18. ↵
    1. Narishetty S. T. K.,
    2. Panchagnula R.

    Transdermal delivery system for zidovudine: in vitro, ex vivo and in vivo evaluation. Biopharm. Drug Dispos. 2004, 25 (1), 9–20.

    OpenUrlPubMed
19. ↵
    1. Jain A. K.,
    2. Thomas N. S.,
    3. Panchagnula R.

    Transdermal drug delivery of Imipramine hydrochloride. 1. Effect of terpenes. J. Controlled Release 2002, 79 (1–3), 93–101.

    OpenUrlCrossRefPubMedWeb of Science
20. ↵
    1. Suwanpidokkul N.,
    2. Thongnopnua P.,
    3. Umprayn K.

    Transdermal delivery of zidovudine: the effects of vehicles, enhancers, and polymer membranes on permeation across cadaver pig skin. AAPS PharmSciTech 2004, 5 (3), 48.

    OpenUrl
21. ↵
    1. Bonacucina G.,
    2. Martelli S.,
    3. Palmieri G. F.

    Rheological, mucoadhesive and release properties of carbopol gels in hydrophilic co-solvents. Int. J. Pharm. 2004, 282 (1–2), 115–130.

    OpenUrlPubMed
22. ↵
    1. Bonacucina G.,
    2. Cespi M.,
    3. Falzi M. M.,
    4. Palmieri G. F.

    Rheological, adhesive and release characterization of semisolid Carbopol/tetraglycol systems. Int. J. Pharm. 2006, 307 (2), 129–140.

    OpenUrlPubMed
23. ↵
    1. Martin A.

    Rheology. Physical Pharmacy, 4th ed., Lea and Febgeir: Philadelphia, 1993; pp 453–476.
24. ↵
    1. Araujo A. S. S.,
    2. Storpirtis S.,
    3. Mercuri L. P.,
    4. Carvalho F. M. S.,
    5. Filho M. D. S.,
    6. Matos J. R.

    Thermal analysis of the antiretroviral Zidovudine and evaluation of the compatibility with excipients used in solid dosage forms. Int. J. Pharm. 2003, 260 (2), 303–314.

    OpenUrlPubMed
25. ↵
    1. Barry B. W.,
    2. Bennett S. L.

    Effect of penetration enhancers on the permeation of mannitol, hydrocortisone and progesterone through human skin. J. Pharm. Pharmacol. 1987, 39, 535–546.

    OpenUrlPubMed
26. ↵
    1. Yamane M. A.,
    2. Williams A. C.,
    3. Barry B. W.

    Terpene penetration enhancers in propylene glycol/water co-solvent systems: effectiveness and mechanism of action. J. Pharm. Pharmacol. 1995, 47 (12A), 978–989.

    OpenUrlPubMedWeb of Science
27. ↵
    1. Kattan A. F.,
    2. Asbil C. S.,
    3. Michniak B. B.

    The effect of terpene enhancer lipophilicity on the percutaneous permeation of hydrocortisone formulated in HPMC gel systems. Int. J. Pharm. 2000, 198 (2), 179–189.

    OpenUrlPubMed
28. ↵
    1. Chiu D. T.,
    2. Duesberg P. H.

    The toxicity of azidothymidine (AZT) on human and animal cells in culture at concentrations used for antiviral therapy. Genetica 1995, 95 (1–3), 103–109.

    OpenUrlPubMed
29. ↵
    1. Hofland J.,
    2. Geest R.,
    3. Bodde H.,
    4. Junginger,
    5. Bouwastra J.

    Estradiol permeation from non-ionic surfactants vesicles through human stratum corneum in vitro. Pharm. Res. 1994, 11 (5), 659–664.

    OpenUrlPubMed
30. ↵
    1. Narishetty S. T. K.,
    2. Panchagnula R.

    Effect of L-menthol and 1,8-cineole on phase behavior and molecular organization of SC lipids and skin permeation of zidovudine. J. Controlled Release 2005, 102 (1), 59–70.

    OpenUrlPubMed